Facilitating a Multi-Institutional Enterprise

促进多机构企业

• 批准号: 10693388
• 负责人: Steven Allan Soper
• 金额: $ 25.81万
• 依托单位: UNIVERSITY OF KANSAS LAWRENCE
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-16 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10693388
• 关键词: Adopted; Advisory Committees; Affect; Annual Reports; Biological; Biological Assay; Biotechnology; Cells; Circulation; Clinical; Collaborations; Commercial Sectors; Committee Members; Communities; Complex; DNA; Data; Development; Devices; Disease; Educational workshop; Epigenetic Process; Evolution; Flow Cytometry; Future; Generations; Goals; Grant; Human Resources; Infrastructure; Injections; Institution; Interdisciplinary Study; Leadership; Length; Microscopy; Mission; Modeling; Modification; Molds; Molecular; Molecular Analysis; Molecular Biology; Nanotechnology; National Institute of Biomedical Imaging and Bioengineering; Nature; Outcome; Output; Participant; Plastics; Private Sector; Privatization; Procedures; Process; Proteins; RNA; Records; Reporting; Research; Research Personnel; Resolution; Resources; Running; Schedule; Scholars Program; Seasons; Secure; Services; Site; Surface; Surveys; System; Talents; Technology; Testing; Training; Training Programs; Translating; United States National Institutes of Health; Update; Vision; Work; cell free DNA; design; experience; extracellular vesicles; fabrication; innovation; instructor; instrumentation; interest; liquid biopsy; manufacture; meetings; member; multidisciplinary; nature center; new technology; organizational structure; precision medicine; program dissemination; programs; prospective; recruit; response; single molecule; skills; success; technology platform; tool; visiting scholar; web site

Title: Biotechnology Resource Center of BioModular Multi-scale Systems (CBM2) for Precision Medicine Administration: Facilitating a Multi-Institutional Enterprise Abstract/Summary The Biotechnology Research Center of BioModular Multi-scale Systems (CBM2) for Precision Medicine, which is seeking to continue its important mission through this competitive renewal application, has outlined an aggressive and highly innovative research program that will generate new technology platforms for the analysis of markers secured from circulation as part of the Liquid Biopsy initiative. These markers include rare biological cells, cell free DNA, and extracellular vesicles as well as the molecular cargo they carry (DNAs, RNAs, and proteins). In its active rendition (2015-2020), CBM2 generated new platforms for the isolation of these liquid biopsy markers and amplification-based molecular assays of their cargo that can be used to guide clinical decisions for a number of important disease states (i.e., Precision Medicine). Unique to this competitive renewal is the evolution of innovative tools to enable the analysis of the liquid biopsy's molecular cargo without requiring amplification that will provide unique opportunities, such as the analysis of epigenetic modifications in DNAs and RNAs. Our platform technology is innovative in that the isolation steps will be integrated to the molecular analysis steps to form fully automated mixed-scale (micro- and nanotechnologies) and modular fluidic systems. The fluidic systems will be populated with task specific modules produced from the expiring P41 as well as innovative ones evolving from the TR&Ds in this competitive renewal. All modules are manufactured in plastics using injection compression molding. The modules can also be used as standalone units to facilitate dissemination. The lofty goals envisioned by CBM2 will be realized through an accomplished multidisciplinary team of researchers across several institutions that possess complementary skill sets. The Administrative Core of the Center will seek to coordinate activities between the Center's researchers to aggressively move the research program forward in a timely manner to provide compelling outputs that will not only provide unique opportunities for the Center's Collaborative and Service Projects, but the biomedical community as a whole. The Center's leadership team is seasoned with extensive experiences in managing large research organizations that have demonstrated success within the research community as well as generating compelling training programs for a variety of audiences with an interest in liquid biopsies and mixed-scale fabrication. The Leadership Team will coordinate the research efforts of the Center with its Collaborative Projects to allow for application driven development of the proposed technologies. The Center is well versed in transitioning its technologies into the commercial sector to facilitate dissemination that will increase Center visibility through Service Projects. The system design approach adopted by the Center (modular format) will facilitate the generation of integrated fluidic systems for automating complex assays. Collaborative and Service Projects will also evolve from the Center through the engaging Training and Dissemination Program including a robust website and extensive networks provided by the Leadership Team as well as an active Visiting Scholar's Program.

标题：精准医学生物模块化多尺度系统（CBM2）生物技术资源中心 管理：促进多机构企业 摘要/总结 精准医学生物模块化多尺度系统（CBM2）生物技术研究中心， 正在寻求通过这个有竞争力的续订应用程序继续其重要使命，概述了 积极且高度创新的研究计划将产生新的分析技术平台 作为液体活检计划的一部分，从循环中获取标记物。这些标记包括罕见的生物标记 细胞、无细胞 DNA 和细胞外囊泡以及它们携带的分子货物（DNA、RNA 和 蛋白质）。在其活跃的表现（2015-2020）中，CBM2 生成了用于隔离这些液体的新平台 活检标记物及其货物的基于扩增的分子测定可用于指导临床 针对许多重要疾病状态的决策（即精准医学）。这种竞争性更新的独特之处 是创新工具的发展，无需任何操作即可分析液体活检的分子货物 扩增将提供独特的机会，例如 DNA 中表观遗传修饰的分析和 RNA。我们的平台技术具有创新性，因为分离步骤将集成到分子分析中 形成全自动混合规模（微米和纳米技术）和模块化流体系统的步骤。流体 系统将填充由即将到期的 P41 以及创新模块生成的任务特定模块 在这场竞争更新中从 TR&D 演变而来。所有模块均采用塑料注塑制造 压缩成型。这些模块还可以用作独立单元以促进传播。 CBM2 所设想的崇高目标将通过一支由多学科专家组成的团队来实现 多个机构的研究人员拥有互补的技能。行政核心 中心将寻求协调中心研究人员之间的活动，以积极推动研究 及时推进计划以提供引人注目的成果，这不仅会提供独特的机会 对于中心的合作和服务项目，而是整个生物医学界。该中心的 领导团队在管理大型研究组织方面经验丰富， 在研究界取得了成功，并为研究人员制定了引人注目的培训计划 对液体活检和混合规模制造感兴趣的各种观众。领导团队将 协调中心的研究工作及其合作项目，以实现应用驱动 拟议技术的开发。该中心擅长将其技术转化为 商业部门促进传播，通过服务项目提高中心的知名度。这 该中心采用的系统设计方法（模块化格式）将促进集成流体的生成 用于自动化复杂测定的系统。协作和服务项目也将从该中心发展而来 通过有吸引力的培训和传播计划，包括强大的网站和广泛的网络 由领导团队以及活跃的访问学者计划提供。